Sumitomo Chemicals product launches and parent-led capex underpin growth outlook

Investment View and Valuation

ICICI Direct Research maintains its BUY recommendation on Sumitomo Chemicals and has set a target price of Rs 625, based on 45 times FY28E EPS of Rs 13.9. The broker views the company’s increasing engagement with parent Sumitomo Chemical Company, Japan (SCC), product pipeline and parent-led manufacturing investments as key differentiators versus other multinational agrochemical companies.

Business Profile and Product Mix

Sumitomo Chemicals India (SCIL), SCC’s Indian subsidiary, supplies insecticides, herbicides, metal phosphates and fungicides. India accounted for approximately 87 per cent of the product mix in Q1 FY27, while exports contributed 13 per cent.

Resilient Q1 FY27 Performance

Reported revenue was Rs 1,063 crore, flat year on year against a high base in Q1 FY26. Insecticide revenue was flat, while herbicide revenue, which represented 31 per cent of revenue, declined 8 per cent. Metal phosphates and AND and EHD, accounting for 10 per cent and 13 per cent respectively, grew 26 per cent and 19 per cent.

Gross margin improved because of price hikes. Despite flat revenue, EBITDA increased 6 per cent year on year to Rs 233 crore, while EBITDA margin expanded approximately 120 basis points to 21.9 per cent. PAT rose approximately 20 per cent year on year to Rs 214 crore.

Domestic Weakness and Export Growth

Domestic revenue declined approximately 3 per cent to Rs 893 crore, while export revenue rose approximately 26 per cent to Rs 170 crore. Export growth was supported by South America, Asia excluding India and Africa, partly offset by weaker sales in Japan and North America.

The operating environment remained difficult because of the delayed South-West monsoon, a 40 per cent rainfall deficit until June-end, lower reservoir levels and an approximately 20 per cent decline in early kharif sowing. High channel inventory after advance purchases during March and April, followed by price corrections, also weighed on demand.

August rainfall is important for a recovery in volumes and channel inventory clearance during Q2 FY27. Management expects a gradual recovery in sowing activity as monsoon progress improves.

Product Pipeline Supports Growth Outlook

ICICI Direct considers the product pipeline a key growth driver. SCIL launched seven large products in FY26, including Lentigo, Excalia Max, Powerpull, Advika, Envoy and Oslava. Lentigo and Excalia Max received a favourable market response and exceeded internal targets.

• Products launched over the past three years contributed 8 per cent of domestic revenue.
• Topgrain and Helibax, a Pyridalyl plus Emamectin product, remain scheduled for launch in Q2 FY27.
• Three to four additional SCC parent products are also in the pipeline.

Parent Support and Manufacturing Investments

SCC has elevated SCIL to the same tier as Japan, the US, Brazil and Europe for early-stage trials of new molecules. ICICI Direct interprets this as evidence of the parent’s confidence in SCIL’s technical capabilities.

SCC is evaluating a semiconductor chemicals opportunity in India, with discussions involving government agencies and customers ongoing. SCIL’s Rs 150 crore Dahej capex for high-value patented molecules for SCC is on track for commercialisation from Q2 FY29. Projects at Bhavnagar and Tarapur serving parent requirements are targeted for commissioning by Q4 FY27. The report cites cumulative investments of approximately Rs 225 crore announced in May 2025 and January 2026.

Financial Forecasts

Key Risks

• Lower-than-expected offtake of new products.
• Adverse weather conditions in domestic and export markets.